Education
About Us
Working with TipRanks
Follow Us
Accelerate Diagnostics (AXDXQ)
OTHER OTC:AXDXQ
Top Page
Accelerate Diagnostics
(OTC:AXDXQ)
Rating:37Underperform
Price Target:
$0.00
▼(-100.00% Downside)
Accelerate Diagnostics (AXDXQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.00
Dividend YieldN/A
Average Volume (3M)3.78M
Price to Earnings (P/E)―
Beta (1Y)-0.04
Revenue Growth-2.99%
EPS Growth59.87%
CountryUS
Employees107
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,516,000
10 Day Avg. Volume142,852
30 Day Avg. Volume3,776,765
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Accelerate Diagnostics Business Overview & Revenue Model
Company DescriptionAccelerate Diagnostics (AXDXQ) is a healthcare technology company focused on improving the diagnosis of infectious diseases. The company specializes in the development and commercialization of innovative diagnostic solutions that enhance the speed and accuracy of pathogen identification and antibiotic susceptibility testing. Its core product offerings include the Accelerate Arc system and related assays, which are designed to deliver rapid results for critical care settings and support healthcare providers in making informed treatment decisions.
How the Company Makes MoneyAccelerate Diagnostics generates revenue primarily through the sale of its diagnostic systems and related consumables, including assays for pathogen detection and antibiotic susceptibility testing. The company's revenue model is based on a combination of system sales, recurring revenue from consumable test kit sales, and service agreements for system maintenance. Key revenue streams include direct sales to hospitals and laboratories, as well as potential partnerships with larger healthcare organizations and distributors that facilitate broader market access. Additionally, Accelerate may benefit from reimbursements from healthcare payers for diagnostic testing services, which can further enhance its earnings.
Accelerate Diagnostics Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q3-2024)
| % Change Since: -97.87%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed view with several positive achievements such as progress in clinical trials, FDA clearance for new systems, and improved gross margins. However, these were balanced by challenges like decreased net sales and ongoing net losses. The strategic focus on innovation and market leadership is promising, yet financial metrics indicate areas needing attention.Q3-2024 Updates
Positive Updates
Clinical Trial Progress for WAVE System
The clinical trial for the WAVE system and Gram-Negative testing menu is on track with external site enrollments meeting expectations. Submission to the FDA is anticipated in Q1 of 2025 with a review timeline of approximately 9 months.
FDA 510(k) Clearance Obtained for Arc System
The Arc system, which includes the blood culture kit, received FDA 510(k) clearance. This platform is designed to reduce diagnostic turnaround times in clinical settings, especially for conditions like sepsis.
Increased Gross Margin
Gross margin was approximately 29% for the quarter, a significant increase from approximately 3% in the same period in the prior year. This was driven by product mix and an inventory write-down in the prior period.
Reduction in SG&A and R&D Expenses
SG&A expenses were reduced to approximately $5.6 million from $7.8 million, and R&D expenses were reduced to $3.8 million from $7 million compared to the same period in the prior year.
Strong Reduction in Cash Used
Cash used for the quarter was approximately $5.5 million, with a strong reduction in cash used from operations down over $2 million quarter-over-quarter.
Negative Updates
Decrease in Net Sales
Net sales were approximately $3 million for the quarter, down from approximately $3.3 million for the same period in the prior year, primarily due to lower instrument sales.
Ongoing Net Loss
The net loss for the quarter was approximately $14.6 million, resulting in a loss per share of $0.59.
Company Guidance
In the third quarter of 2024, Accelerate Diagnostics, Inc. demonstrated significant advancements and provided detailed guidance on their strategic initiatives. The company reported net sales of approximately $3 million, a slight decrease from $3.3 million the previous year, but saw a high single-digit increase in consumable-related product sales. Gross margin improved to 29% from 3% due to favorable product mix and inventory adjustments. Selling, general, and administrative expenses were reduced to $5.6 million, with research and development expenses also decreasing to $3.8 million, reflecting a focus on lower third-party development costs for the WAVE program. The company's net loss was reported at $14.6 million, equating to a loss per share of $0.59. Despite these financial metrics, Accelerate Diagnostics highlighted strong progress in the clinical trial of their WAVE system, on track for FDA submission in Q1 2025 with a review timeline of approximately nine months. Additionally, their recent FDA 510(k) clearance for the Accelerate Arc system marked a pivotal achievement, promising reduced diagnostic turnaround times and improved antimicrobial stewardship, while their commercial strategy aims to secure long-term contracts and expand market reach beyond the U.S. and EMEA regions. The company maintains a cash burn target of $5 million per quarter, anticipating sufficient operating cash through the end of 2025, contingent upon third-party product partnership payments.Accelerate Diagnostics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Accelerate Diagnostics Technical Analysis
Negative
0.01
Price Trends
0.41
Negative
0.79
Negative
1.22
Negative
Market Momentum
-0.13
Negative
13.37
Positive
29.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXDXQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.41, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 13.37 is Positive, neither overbought nor oversold. The STOCH value of 29.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AXDXQ.
Accelerate Diagnostics Risk Analysis
Accelerate Diagnostics disclosed 52 risk factors in its most recent earnings report. Accelerate Diagnostics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Accelerate Diagnostics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.83B | -0.15 | -40.10% | 2.29% | 21.46% | -2.01% | |
49 Neutral | $8.73M | ― | -72.70% | ― | 5.05% | 26.13% | |
46 Neutral | $56.88M | ― | -68.84% | ― | -7.81% | 65.39% | |
45 Neutral | $12.20M | ― | -63.40% | ― | -91.14% | 9.47% | |
44 Neutral | $69.38M | ― | -230.80% | ― | -16.46% | 4.16% | |
37 Underperform | $25.00 | ― | ― | -2.99% | 59.87% | ||
29 Underperform | $2.12M | ― | -96.69% | ― | ― | 98.25% |
* Healthcare Sector Average
Performance Comparison
AXDXQ
Accelerate Diagnostics
0.01
-1.88
-99.47%
CTSO
Cytosorbents
0.93
-0.08
-7.92%
BMRA
Biomerica
3.29
-0.39
-10.60%
CODX
Co-Diagnostics
0.31
-1.26
-80.25%
ICCM
Icecure Medical
0.98
0.34
53.12%
BJDX
Bluejay Diagnostics
1.36
-8.52
-86.23%
Accelerate Diagnostics Corporate Events
Delistings and Listing ChangesLegal Proceedings
Accelerate Diagnostics Liquidation Plan Confirmed by Court
Negative
Aug 18, 2025
On May 8, 2025, Accelerate Diagnostics, Inc. and its subsidiary filed for Chapter 11 bankruptcy, and subsequently, on May 30, 2025, entered into an asset purchase agreement with Indaba Capital Management to sell most of its assets. The sale was approved on July 14, 2025, and later amended on August 8, 2025, to include specific assets and liabilities. On August 13, 2025, the court confirmed the company’s liquidation plan, which will cancel all outstanding shares of common stock, leaving shareholders with no property. The effective date of the plan is expected around August 18, 2025.
Legal ProceedingsBusiness Operations and Strategy
Accelerate Diagnostics Files for Chapter 11 Bankruptcy
Negative
Jun 4, 2025
On May 8, 2025, Accelerate Diagnostics, Inc. and its US subsidiary filed for Chapter 11 bankruptcy protection, initiating a sale process for substantially all of its assets. The company entered into an asset purchase agreement with Indaba Capital Management, its secured noteholder, to sell its assets, subject to court approval and competitive bidding procedures. This move is part of a strategic effort to manage its financial obligations and is expected to significantly impact stakeholders, with the company cautioning that common stockholders may face substantial losses.
Executive/Board Changes
Accelerate Diagnostics CFO Resignation Announced
Neutral
May 28, 2025
On May 21, 2025, David Patience announced his resignation as Chief Financial Officer of Accelerate Diagnostics, effective June 30, 2025, to pursue other professional opportunities. His departure is not due to any disagreements with the company’s operations or policies, suggesting a smooth transition and stability in the company’s management.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.